Head of the "Molecular engineering of proteins (SIMOPRO)" laboratory and leader of the the "Function of zinc metalloproteases" group, CEA Saclay.
Dr. Vincent DIVE has a long-standing expertise in the chemistry of phosphorus-containing peptides as potent inhibitors of zinc-metalloproteinases and evaluation of their in vivo activity. Labelling of drugs with 3H and 14C in combination with radioimaging is routinely used to study the in vivo biodistribution of corresponding drugs.
Dr. Dive’s group has been involved in multiple European Integrated projects (FP4, FP5, FP6 and FP7) dealing with the development of inhibitors of zinc proteases (MMPs, ACE, ACE2) for cancer and cardiovascular applications. In collaboration with VECT-HORUS, the use of these inhibitors to target brain diseases has been recently initiated.
He has co-authored more than 130 peer-reviewed scientific publications and he was named in 11 patent applications covering cancer and cardiovascular applications of phosphinic peptides.
In 2006, Vincent Dive became the head of the SIMOPRO Section (Service d’Ingénierie Moléculaire des Protéines), a section developing small peptides or proteins for diagnosis or therapeutic applications.
Dr. Dive’s research is focused on the development of phosphinic peptides as potent inhibitors of zinc-proteases for therapeutic, molecular imaging and proteomics applications and has developed solid-phase synthesis and combinatorial chemistry of this family of pseudo-peptides.
The team has been selected in 2011, as a member of the Laboratory of Excellence funded through the “Investments in the Future programme”, The Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).